[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Points of consideration for pluripotent stem cell culture

DOI
  • Aoi Takashi
    Division of Advanced Medical Science, Graduate School of Science, Technology and Innovation, and Department of iPS cell Applications, Graduate School of Medicine, Kobe University
  • Asaka Isao
    Department of Fundamental Cell Technology, Center for iPS Cell Research and Application (CiRA), Kyoto University
  • Akutsu Hidenori
    Department of Reproductive Medicine, National Research Institute for Child Health and Development
  • Ito Yuzuru
    Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology
  • Kataoka Ken
    Department of Life Science, Faculty of Science, Okayama University of Science
  • Kanda Yasunari
    Division of Pharmacology, National Institute of Health Sciences
  • Kojima Hajime
    Division of Risk Assessment, National Institute of Health Sciences
  • Sekino Yuko
    Endowed Laboratory of Human Cell-Based Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Tokyo
  • Suemori Hirofumi
    Laboratory of Embryonic Stem Cell Research, Institute for Frontier Life and Medical Sciences, Kyoto University
  • Nakagawa Masato
    Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University
  • Nakamura Kazuaki
    Department of Pharmacology, National Research Institute for Child Health and Development
  • Nakamura Yukio
    Cell Engineering Division, RIKEN BioResource Research Center
  • Fujii Makiko
    International Collaboration Development for Dentistry, School of Density, Hiroshima University
  • Furue Miho K
    Laboratory of Stem Cell Cultures, National Institutes of Biomedical Innovation, Health and Nutrition
  • Yamazaki Daiju
    Division of Pharmacology, National Institute of Health Sciences

Bibliographic Information

Other Title
  • 「多能性幹細胞培養の留意点」の提案

Search this article

Abstract

<p>In recent years, human pluripotent stem cells such as human embryonic stem (ES) cells and human inducible pluripotent stem (iPS) cells have been widely used not only in basic research but also in drug discovery research and application to regenerative medicine. Simultaneously, because the research environment including supply of cultivation materials has been improved, culture of human pluripotent stem cells can be easily carried out, and the number of researchers using human pluripotent stem cells is increasing. On the other hand, it is important points for researchers/engineers to share the basic concepts of technology and its background and to ensure the reproducibility of the research results. Characters of human pluripotent stem cells are significantly different from that of somatic cells that have been used in the past, and there are many points to keep in mind even if researchers/engineers have a vast experience in culturing mammalian cells. Therefore, we hope that human pluripotent stem cells will be usefully utilized and drew a draft guidance of “key points of consideration for pluripotent stem cell culture”. This draft describes the contents to be confirmed at the start of use of human pluripotent stem cells in seven sections (agreed with laws and regulations/guidelines/MTA, diversity of pluripotent stem cell, culture material, thawing operation, medium exchange and passage, freezing operation, and culture management). We propose here the guidance as the concept shared by researchers and engineers who carry out cell culture of pluripotent stem cells, and hope that utilization and reliability of research using pluripotent stem cells will improve.</p>

Journal

Details

Report a problem

Back to top